Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521861

SCHEMBL1521861

SCHEMBL1521861

CCN1C(=O)N(c2cc(NC(=O)Nc3cc(C(C)C)no3)c(F)cc2Cl)Cc2cnc(NC)nc21

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.39
▸ FGFR4 P22455 12/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TNK2 Q07912 1/20 0.37
▸ MAP4K2 Q12851 1/20 0.37
▸ FGFR1 P11362 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KRAS P01116 1/20 0.34
▸ RAF1 P04049 1/20 0.34
▸ BRAF P15056 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ MAP2K2 P36507 1/20 0.34
▸ MAP2K1 Q02750 1/20 0.34
▸ NEK7 Q8TDX7 1/20 0.33
▸ FGFR2 P21802 1/20 0.33
▸ FGFR3 P22607 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521751 0.93 TNK2 (0.42) MAPK14FGFR4TNK2MAP4K2FGFR1
SCHEMBL1521679 0.90 BRAF (0.45) MAPK14FGFR4TNK2MAP4K2FGFR1
SCHEMBL1521610 0.87 KRAS (0.39) MAPK14FGFR4SMN1; SMN2TNK2MAP4K2
SCHEMBL1521994 0.87 MAPK14 (0.40) MAPK14FGFR4SMN1; SMN2FGFR1ALDH1A1
SCHEMBL1521781 0.83 BRAF (0.46) MAPK14FGFR4TNK2MAP4K2FGFR1
SCHEMBL1521858 0.82 BRAF (0.46) MAPK14FGFR4TNK2MAP4K2ALDH1A1
SCHEMBL1521731 0.80 TNK2 (0.45) MAPK14FGFR4TNK2MAP4K2FGFR1
SCHEMBL1521672 0.80 BRAF (0.40) MAPK14FGFR4SMN1; SMN2FGFR1ALDH1A1
SCHEMBL1521753 0.77 BRAF (0.51) MAPK14FGFR4FGFR1ALDH1A1KRAS
SCHEMBL1521670 0.77 BRAF (0.51) MAPK14FGFR4TNK2MAP4K2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 MAPK14 240/4885FGFR4 1073/4885SMN1; SMN2 4182/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPK14 240/4885FGFR4 1073/4885SMN1; SMN2 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.